Earnings
The week began with new partnerships formed in the life sciences industry as several firms entered into licensing deals and collaboration commitments. Here’s a look at the latest.
GENFIT delivered on its promise to improve its financial situation in the year to December 31, 2021, posting an income of $40.8 million USD from a loss of $20.3 million in the year prior.
Proceeds from the Series A will be used to further advance the company’s Kinetic Ensemble platform and accelerate its R&D pipeline.
The AMR Action Fund financed two of this week’s money moves. Other moves ranged from medical devices to wearable sensor data companies. For that and more, continue reading.
Here’s a look at the eight most profitable biopharma companies around the world. Profitability, in this case, refers to net income, as opposed to total revenue or sales.
Boehringer Ingelheim made a splash on Tuesday, announcing its intention to pump €25 billion ($27 billion) into its R&D pipeline over the next five years.
Silverback is halting its clinical oncology programs and letting go of about 27% of its workforce as part of a restructuring initiative that would leave it with more cash reserves.
Ginkgo Bioworks reported its 2021 financials today, and the $1.7 billion of stock-based compensation caught everyone’s attention.
Sanofi inked a pact with IGM Biosciences that could pass $6 billion. However, Sanofi CEO Paul Hudson’s pay had a drop of about 3.7%, according to the company’s annual filing.
After manufacturing more than 2.6 billion doses of the Comirnaty COVID-19 vaccine together, Pfizer’s partner BioNTech is reporting skyrocketing profits.
PRESS RELEASES